P2855Unexpectedly high rate of lead failure of the Microport (formerly Sorin/Livanova) Beflex and Vega pacemaker electrodes: A single centre experience

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
M Anwander ◽  
T Kueffer ◽  
M Branca ◽  
R Sweda ◽  
N Nozica ◽  
...  
Keyword(s):  
Right Ventricular ◽  
Weak Link ◽  
High Rate ◽  
High Threshold ◽  
Manufacturing Companies ◽  
Single Centre ◽  
Lead Failure ◽  
Post Marketing ◽  
Pacing Leads

Abstract Introduction Pacing leads remain the weak link of current pacemaker systems. Various differences in design and material exist among companies. Lead performance is mainly assessed via post-marketing studies of the manufacturing companies. Reliable independent reports are rare. We aimed to study the early and long-term performance of the Microport (formerly Sorin/Livanova) Beflex and Vega leads at our centre, for which a lead survival >99% at 3 years has been reported by the company. Method In this single centre, retrospective study we analysed the performance of all right ventricular Microport pacemaker leads implanted at our centre between January 2014 and January 2018. Only first pacemaker implants were considered. Lead failure was defined as any lead issue requiring reintervention during follow-up (dislocation, perforation, electrical abnormalities such as lead noise or excessively high thresholds). Results A total of 271 Microport right ventricular pacing leads were implanted (233 Beflex and 38 Vega leads). Mean patient age was 76±13.1 years (66% men). Dual chamber pacemakers were implanted in 162 patients (60%) and single chamber in 109 (40%). Mean threshold at implant was 0.6V/0.5ms (range 0.3–1.2V), mean R wave 13.2 mV (range 1.5–30mV) and mean impedance 816 Ohm (range 469–1639 Ohm). Patients without available follow-up information were excluded (N=18, 6.6%). The remaining 253 patients (93.4%) were analysed. Median follow-up was 1.26 years, IQR [25%=0.91 and 75%=2.24]. We observed a total of 25 lead failures (10%). Lead dislocation occurred in 2 cases (0.8%), lead perforation in 5 cases (2%), electrical abnormalities in 6 cases (2.4%) and excessively high threshold in 12 cases (4.8%; mean voltage 4V, range 2–7.5V; mean pulse width 0.75ms, range 0.35–1ms). Yearly incidence of lead failure per 100 leads was 6.1% (95%-CI [4.09–8.98] with a failure rate of 12.74% at 3 year in Kaplan-Meier analysis (Figure). Figure 1 Conclusion We found an unexpectedly high rate of lead failure of the Microport Beflex and Vega pacing leads at our centre. The two main reasons for premature lead failure were excessively high thresholds as well as electrical abnormalities during follow-up. Comparison of lead performance with other centres and against other leads are needed to further assess the magnitude of the problem.

Incidence of Premature Lead Failure in 2088 TendrilTM Pacing Leads: A Single Centre Experience

2020 ◽  
Author(s):  
Louise Segan ◽  
Rohit Samuel ◽  
Michael Lim ◽  
Daryl Ridley ◽  
Jonathan Sen ◽  
...  
Keyword(s):  
Single Centre ◽  
Lead Failure ◽  
Single Centre Experience ◽  
Pacing Leads

P1147Complications in young ICD patients - a retrospective analysis

EP Europace ◽  
2020 ◽  
Vol 22 (Supplement_1) ◽  
Author(s):  
D Zweiker ◽  
T Puntus ◽  
F Egger ◽  
R Kriz ◽  
J Koch ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Young Patients ◽  
High Rate ◽  
Complication Rates ◽  
Active Lifestyle ◽  
Icd Implantation ◽  
Lead Failure ◽  
Icd Therapy ◽  
Ventricular Lead

Abstract Introduction In specific situations implantable cardioverter defibrillator (ICD) therapy is recommended for patients under the age of 40 years. Due to the active lifestyle of this patient population, complication rates in devices with conventional transvenous electrodes may be higher than for the remaining population. Methods The ICD-YOUNG study is a retrospective analysis of consecutive patients ≤ 40 years undergoing transvenous or subcutaneous ICD (s-ICD) implantation, device change or lead revision at our centre between July 2006 and December 2017. Rehospitalization for lead failure or device battery depletion was documented. Results Out of 586 patients undergoing ICD implantation, 35 patients (6.0%) were ≤ 40 years. Mean age was 30.0 ± 7.2 years, 48.6% were female, 37.1% received ICD therapy for primary prevention and 11.4% primarily received s-ICD. Median follow up was 7.3 (interquartile range, 1.8-12.0) years, with a lower follow up duration in s-ICD patients than conventional ICD patients (median, 2.9 vs. 9.0 years). Over the course of follow-up, 37.1% received successful anti-tachycardia therapy. 19.4% of patients in the conventional ICD group had right ventricular lead problems requiring intervention, while none of the s-ICD patients had to be revised. Time to first device change due to battery depletion and/or device upgrade was similar in young and remaining patients (median 5.4 vs 6.0 years, p = 0.23). Discussion Young patients requiring ICD have a high rate of lead problems. In most young patients, s-ICD therapy is an encouraging alternative to conventional ICD therapy with a lower lead failure rate.

scholarly journals REPEAT CHEST CT SCANS IN MODERATE-TO-SEVERE PATIENTS’ MANAGEMENT DURING THE COVID-19 PANDEMIC: OBSERVATIONS FROM A SINGLE CENTRE IN WUHAN, CHINA

2020 ◽  
Vol 190 (3) ◽  
pp. 269-275
Author(s):  
Lang Chen ◽  
Qiuxia Wang ◽  
Hongyu Wu ◽  
Junwu Hu ◽  
Jing Zhang
Keyword(s):  
Clinical Utility ◽  
Disease Duration ◽  
Value Added ◽  
Healthcare Systems ◽  
Chest Ct ◽  
High Rate ◽  
Single Centre ◽  
Computed Tomographic ◽  
Repeat Chest

Abstract Objective To observe the rates of repeated computed tomographic scans (CTs) in a cohort of patients with coronavirus disease-2019 (COVID-19) and to assess the validity of repeat CTs. Methods Each CT was recorded, and the validity of the repeated CTs was assessed. Results The 394 patients underwent a total of 1493 CTs. Of the 394 patients, 260 received at least one non-value-added CT. Both the total number of CTs (median, 4; interquartile range (IQR), 3–5) and non-value-added CTs (median, 1; IQR, 0–1) per patient were strongly related to the disease duration (R2 = 0.566 for total CTs, R2 = 0.432 for non-value-added CTs, p < 0.001). The proportion of non-value-added CTs was potentially higher after 3 weeks from symptom onset (>35%). Conclusions There was a high rate of repeat CTs for the COVID-19 patients, and the proportion of non-value-added CTs increased with disease duration. Follow-up CT should be avoided without clinical decline. Advances in Knowledge As COVID-19 is impacting healthcare systems across the globe, we believe in our findings that serial chest CT imaging has limited clinical utility in basically stable COVID-19 patients, will help relieve some of this burden.

scholarly journals Long-Term Follow Up of Ventricular Endocardial Pacing Leads. Complications, Electrical Performance, and Longevity of 561 Right Ventricular Leads.

1993 ◽  
Vol 34 (2) ◽  
pp. 193-200 ◽  
Author(s):  
Shigeru KAZAMA ◽  
Kiyotaka NISHIYAMA ◽  
Masato MACHII ◽  
Katsuhiko TANAKA ◽  
Takaomi AMANO ◽  
...  
Keyword(s):  
Right Ventricular ◽  
Electrical Performance ◽  
Long Term Follow Up ◽  
Endocardial Pacing ◽  
Pacing Leads

High rate of SVR with DAA in haemophiliacs with HCV infection: Three decades of follow‐up of a Portuguese single‐centre cohort

2020 ◽  
Vol 40 (7) ◽  
pp. 1783-1784
Author(s):  
Tiago P. Guedes ◽  
Mónica Garrido ◽  
Sara Morais ◽  
Isabel Pedroto
Keyword(s):  
Hcv Infection ◽  
High Rate ◽  
Single Centre

Periprocedural risk and long-term outcome of intracranial angioplasty based on a single-centre experience

VASA ◽  
2013 ◽  
Vol 42 (4) ◽  
pp. 264-274
Author(s):  
Dagmar Krajíčková ◽  
Antonín Krajina ◽  
Miroslav Lojík ◽  
Martina Mulačová ◽  
Martin Vališ
Keyword(s):  
Death Rate ◽  
Long Term Outcomes ◽  
Single Centre ◽  
Intracranial Atherosclerotic Stenosis ◽  
Atherosclerotic Stenosis ◽  
Angioplasty And Stenting ◽  
Aggressive Medical Management ◽  
Stroke Death

Background: Intracranial atherosclerotic stenosis is a major cause of stroke and yet there are currently no proven effective treatments for it. The SAMMPRIS trial, comparing aggressive medical management alone with aggressive medical management combined with intracranial angioplasty and stenting, was prematurely halted when an unexpectedly high rate of periprocedural events was found in the endovascular arm. The goal of our study is to report the immediate and long-term outcomes of patients with ≥ 70 % symptomatic intracranial atherosclerotic stenosis treated with balloon angioplasty and stent placement in a single centre. Patients and methods: This is a retrospective review of 37 consecutive patients with 42 procedures of ballon angioplasty and stenting for intracranial atherosclerotic stenosis (≥ 70 % stenosis) treated between 1999 and 2012. Technical success (residual stenosis ≤ 50 %), periprocedural success (no vascular complications within 72 hours), and long-term outcomes are reported. Results: Technical and periprocedural success was achieved in 90.5 % of patients. The within 72 hours periprocedural stroke/death rate was 7.1 % (4.8 % intracranial haemorrhage), and the 30-day stroke/death rate was 9.5 %. Thirty patients (81 %) had clinical follow-up at ≥ 6 months. During follow-up, 5 patients developed 6 ischemic events; 5 of them (17 %) were ipsilateral. The restenosis rate was 27 %, and the retreatment rate was 12 %. Conclusions: Our outcomes of the balloon angioplasty/stent placement for intracranial atherosclerotic stenosis are better than those in the SAMMPRIS study and compare favourably with those in large registries and observational studies.

Sign in / Sign up

Export Citation Format

Share Document